IP Library › Granted Patent US 50,908
Granted Patent E1
US 50,908 · App. 17/314,828 · Granted Jun 9, 2026

Vaccine compositions and methods for restoring NKG2D pathway function against cancers

Inventors: Glenn Dranoff (Sudbury, MA); Kai W. Wucherpfennig (Brookline, MA); Christopher Harvey (Boston, MA); F. Stephen Hodi (Framingham, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
A61K39/0011A61K45/06C07K14/70539A61K2039/5152A61K2039/6037
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 50,908
App. No.
17/314,828
Granted
Jun 9, 2026
Kind
E1
Abstract

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.

Claims (81)

1 . A vaccine composition for treating cancer, the composition comprising

(i) as an immunogenic component, an effective amount of a peptide selected from the group consisting of:

(a) amino acids 181 179 to 274 of SEQ ID NO: 1, having up to five amino acid modifications;

(b) SEQ ID NO: 2, 11, 12, 13, 21 or 23, wherein SEQ ID NO: 2 has up to six amino acid modifications, SEQ NO ID: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications;

(c) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having 2, 4, 5, 6, 8, or 10 flanking amino acids on either the N-terminal end of the peptide, the C-terminal end of the peptide, or both the N-terminal end and the C-terminal end ends of the peptide,

wherein SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications, and

wherein the flanking amino acids are amino acids adjacent to SEQ ID NO: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; or

(d) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having one or more flanking amino acids such that the entire peptide consists of is about 25 to 30 amino acids,

wherein SEQ ID NO: 11, 13, 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications; and

wherein the flanking amino acids are amino acids adjacent to SEQ ID NO: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; and

(e) amino acids 170 to 268 of SEQ ID NO: 14, having up to nine amino acid modifications;

the effective amount being an amount effective to elicit that elicits an immune response against the cancer;

wherein flanking amino acids are amino acids adjacent to SEQ ID NO:11, 12, 13, 21 or 23 in SEQ ID NO: 1 or in SEQ ID NO: 14; and

(ii) an adjuvant selected from the group consisting of an oil-based adjuvant, a CpG DNA adjuvant, a mineral salt adjuvant, a particulate adjuvant, a mucosal adjuvant, a cytokine, a microbial derivative, an emulsion and a Toll-Like Receptor agonist.

2 . The vaccine composition of claim 1 , wherein the composition is effective to elicit an in vitro immune response against a MIC polypeptide.

3 . The vaccine composition of claim 1 , wherein the composition is effective to elicit an in vivo immune response against a MIC polypeptide.

4 . The vaccine composition of claim 2 , wherein the MIC polypeptide is not attached to a cell.

5 . The vaccine composition of claim 1 , wherein the composition is effective to elicit an immune response against a cancer cell expressing a MIC polypeptide.

6 . The vaccine composition of claim 1 2 , wherein the MIC polypeptide is a MICA or MICB polypeptide.

7 . The vaccine composition of claim 1 , wherein the cancer expresses MICA and/or MICB proteins.

8 . The vaccine composition of claim 1 , wherein the cancer is melanoma.

9 . The vaccine composition of claim 1 , wherein the peptide consists of SEQ ID NO: 2, 5-13, 15-21 or 23 is selected from the group consisting of:

SEQ ID NO: 2 or amino acids 170 to 268 of SEQ ID NO: 14, having up to six amino acid modifications;

SEQ ID NO: 9 or 19, having up to four amino acid modifications;

SEQ ID NO: 5, 7, 10, 15 or 20, having up to three amino acid modifications;

SEQ ID NO: 6, 8, 12, 16, 18 or 23, having up to two amino acid modifications; and

SEQ ID NO: 11, 13, 17 or 21, having up to one amino acid modification.

10 . The A vaccine composition of claim 1 , wherein the vaccine composition an immunogenic component comprises a plurality of peptides of claim 1 , consisting of one or more of:

(a) amino acids 181 179 to 274 of SEQ ID NO: 1, having up to five amino acid modifications;

(b) SEQ ID NO: 2, 11, 12, 13, 21 or 23, wherein SEQ ID NO: 2 has up to six amino acid modifications, SEQ ID NO: 11, 13 and 21 have up to one amino acid modification, and SEQ ID NO: 12 and 23 have up to two amino acid modifications;

(c) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having 2, 4, 5, 6, 8, or 10 flanking amino acids on either the N-terminal end of the peptide, the C-terminal end of the peptide, or both the N-terminal end and the C-terminal end ends of the peptide,

wherein SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications, and

wherein the flanking amino acids are amino acids adjacent to SEQ NO ID: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; or

(d) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having one or more flanking amino acids such that the entire peptide consists of is about 25 to 30 amino acids,

wherein SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications; and

wherein the flanking amino acids are amino acids adjacent to SEQ ID NO: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; and

(e) amino acids 170 to 268 of SEQ ID NO: 14, having up to nine amino acid modifications.

11 . The vaccine composition of claim 1 , wherein the peptide is conjugated to a carrier protein.

12 . The vaccine composition of claim 11 , wherein the carrier protein is selected from tetanus toxin and diphtheria toxin.

13 . The vaccine composition of claim 1 , wherein the composition comprises a viral capsid protein engineered to display the at least one peptide or plurality of peptides on its surface.

14 . The vaccine composition of claim 13 , wherein the viral capsid protein is a hepatitis B capsid protein.

15 . The vaccine composition of claim 1 , wherein the composition is in the form of a polymer scaffold comprising the peptide.

16 . The vaccine composition of claim 15 , wherein the polymer scaffold is a porous, poly-lactide-co-glycolide (PLG) polymer scaffold.

17 . The vaccine composition of claim 16 , wherein the polymer scaffold further comprises one or both of a cytokine and a Toll-like receptor agonist.

18 . The vaccine composition of claim 17 , wherein the polymer scaffold further comprises autologous tumor cell lysates of a subject to be treated for cancer with the composition.

19 . A method of treating cancer in a subject, the method comprising administering to a subject a vaccine composition of claim 1 .

20 . The method of claim 19 , wherein the vaccine composition is administered as part of a therapeutic regimen.

21 . The method of claim 20 , wherein the therapeutic regimen further comprises one or more of radiation therapy, targeted therapy, immunotherapy, or chemotherapy.

22 . The method of claim 19 , wherein the vaccine composition is administered as part of a prime-boost strategy and the prime-boost strategy further comprises, comprising administering at least one, preferably two additional vaccine compositions of the invention, each vaccine composition composition comprising a different peptide selected from the group of peptides consisting of:

(a) amino acids 181 179 to 274 of SEQ ID NO: 1, having up to five amino acid modifications;

(b) SEQ ID NO: 2, 11, 12, 13, 21 or 23, wherein SEQ ID NO: 2 has up to six amino acid modifications, SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications;

(c) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having 2, 4, 5, 6, 8, or 10 flanking amino acids on either the N-terminal end of the peptide, the C-terminal end of the peptide, or both the N-terminal end and the C-terminal end ends of the peptide,

wherein SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications, and

wherein the flanking amino acids are amino acids adjacent to SEQ ID NO: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; or

(d) SEQ ID NO: 11, 12, 13, 21 or 23, further comprising having one or more flanking amino acids such that the entire peptide consists of is about 25 to 30 amino acids,

wherein SEQ ID NO: 11, 13 and 21 have up to one amino acid modification and SEQ ID NO: 12 and 23 have up to two amino acid modifications; and

wherein the flanking amino acids are amino acids adjacent to SEQ ID NO: 11, 12, 13, 21 or 23 in SEQ ID NO: 1 or 14, having up to three amino acid modifications; and

(e) amino acids 170 to 268 of SEQ ID NO: 14, having up to nine amino acid modifications.

23 . The vaccine composition of claim 3 , wherein the MIC polypeptide is not attached to a cell.

24 . The vaccine composition of claim 1 , wherein the mineral salt adjuvant is a mineral salt gel adjuvant.

25 . The vaccine composition of claim 1 , wherein the particulate adjuvant is a micro particulate adjuvant.

26. The vaccine composition of claim 1 , wherein

if SEQ ID NO: 11 has the flanking amino acids of elements (c) or (d), then the flanking amino acids have up to two amino acid modifications;

if SEQ ID NO: 12 has the flanking amino acids of elements (c) or (d), then the flanking amino acids have up to one amino acid modification;

SEQ ID NO: 2 has up to five amino acid modifications;

amino acids 170 to 268 of SEQ ID NO: 14 has up to four amino acid modifications;

if SEQ ID NO: 21 has the flanking amino acids of elements (c) or (d), then the flanking amino acids have tup to one amino acid modification;

if SEQ ID NO: 13 has the flanking amino acids of elements (c) or (d), then the flanking amino acids have up to one amino acid modification; and,

if SEQ ID NO: 23 has the flanking amino acids of elements (c) or (d), then the flanking amino acids have up to one amino acid modification.

27. The vaccine composition of claim 1 , wherein

amino acid 171 of SEQ ID NO: 1 is replaced with a lysine;

amino acid 173 of SEQ ID NO: 1 is replaced with a glycine;

amino acid 179 of SEQ ID NO: 1, amino acid 4 of SEQ ID NO: 2, or amino acid 1 of SEQ ID NO: 11 is replaced with an arginine;

amino acid 204 of SEQ ID NO: 1, amino acid 29 of SEQ ID NO: 2, or amino acid 6 of SEQ ID NO: 11 is replaced with a glycine;

amino acid 208 of SEQ ID NO: 1, amino acid 33 of SEQ ID NO: 2, or amino acid 10 of SEQ ID NO: 11 is replaced with a tryptophan;

amino acid 213 of SEQ ID NO: 1 or amino acid 38 of SEQ ID NO: 2 is replaced with a serine;

amino acid 249 of SEQ ID NO: 1 or amino acid 74 of SEQ ID NO: 2 is replaced with an arginine;

amino acid 188 of SEQ ID NO: 14 or amino acid 9 of SEQ ID NO: 21 is replaced with an isoleucine;

amino acid 191 of SEQ ID NO: 14 is replaced with a lysine;

amino acid 254 of SEQ ID NO: 14 is replaced with a lysine; or

amino acid 266 of SEQ ID NO: 14 is replaced with a serine.

Continuity (2)
Provisional Application 61953064 · Mar 14, 2014
Reissue 15125882 · Mar 16, 2015
References Cited (370)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545403A · Page · 1996 [cited by applicant]
US 5545405A · Page · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591639A · Bebbington · 1997 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5658759A · Bebbington · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5714350A · Co et al. · 1998 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5981216A · Kenten et al. · 1999 [cited by applicant]
US 5998144A · Reff et al. · 1999 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6091001A · Jakobovits et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6344203B1 · Sandrin · 2002 [cited by examiner]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7771718B2 · Spies et al. · 2010 [cited by applicant]
US 7959916B2 · Spies et al. · 2011 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8182809B1 · Wu · 2012 [cited by applicant]
US 9402905B2 · Wucherpfennig et al. · 2016 [cited by applicant]
US 10106611B2 · Wucherpfennig et al. · 2018 [cited by applicant]
US 10745483B2 · Wucherpfennig · 2020 [cited by examiner]
US 10851148B2 · Cheney · 2020 [cited by examiner]
US 20030022450A1 · Pan et al. · 2003 [cited by applicant]
US 20030099647A1 · Deshpande et al. · 2003 [cited by applicant]
US 20030118592A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20030133939A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20030153043A1 · Carr et al. · 2003 [cited by applicant]
US 20030165835A1 · Spies et al. · 2003 [cited by applicant]
US 20040067503A1 · Tan et al. · 2004 [cited by applicant]
US 20040115198A1 · Spies et al. · 2004 [cited by applicant]
US 20050053608A1 · Weber et al. · 2005 [cited by applicant]
US 20050059087A1 · Weber et al. · 2005 [cited by applicant]
US 20050158307A1 · Spies et al. · 2005 [cited by applicant]
US 20050233391A1 · Spies et al. · 2005 [cited by applicant]
US 20060024297A1 · Wood et al. · 2006 [cited by applicant]
US 20060228349A1 · Acton et al. · 2006 [cited by applicant]
US 20060246071A1 · Green et al. · 2006 [cited by applicant]
US 20070248607A1 · Spies et al. · 2007 [cited by applicant]
US 20080148432A1 · Abad · 2008 [cited by applicant]
US 20090022644A1 · Sweredjuk · 2009 [cited by applicant]
US 20090175821A1 · Bridon et al. · 2009 [cited by applicant]
US 20090226447A1 · Boone et al. · 2009 [cited by applicant]
US 20090252729A1 · Farrington et al. · 2009 [cited by applicant]
US 20100111973A1 · Dranoff et al. · 2010 [cited by applicant]
US 20100189711A1 · Dranoff et al. · 2010 [cited by applicant]
US 20100261269A1 · June et al. · 2010 [cited by applicant]
US 20110311561A1 · Martin, Jr. et al. · 2011 [cited by applicant]
US 20120100182A1 · Mooney · 2012 [cited by applicant]
US 20120315287A1 · Wu · 2012 [cited by applicant]
US 20130202707A1 · Ali et al. · 2013 [cited by applicant]
US 20140004112A1 · Wucherpfennig et al. · 2014 [cited by applicant]
US 20140027630A1 · Musselman · 2014 [cited by applicant]
US 20140037630A1 · Dranoff et al. · 2014 [cited by applicant]
US 20160046716A1 · Wucherpfennig et al. · 2016 [cited by applicant]
US 20170008962A1 · Wucherpfennig et al. · 2017 [cited by applicant]
US 20170022275A1 · Wucherpfennig et al. · 2017 [cited by applicant]
US 20170198054A1 · Harvey et al. · 2017 [cited by applicant]
CN 102911270 · 2013 [cited by applicant]
CN 102911270A · 2013 [cited by applicant]
EP 0154316 · 1985 [cited by applicant]
EP 0401384 · 1990 [cited by applicant]
EP 1176195 · 2002 [cited by applicant]
EP 2336180 · 2011 [cited by applicant]
JP 2008543774 · 2008 [cited by applicant]
JP 2008543774A · 2008 [cited by applicant]
WO WO8807054 · 1988 [cited by applicant]
WO WO8808089 · 1988 [cited by applicant]
WO WO9110741 · 1991 [cited by applicant]
WO WO9402602 · 1994 [cited by applicant]
WO WO9429351 · 1994 [cited by applicant]
WO WO9632478 · 1996 [cited by applicant]
WO WO9633735 · 1996 [cited by applicant]
WO WO9734631 · 1997 [cited by applicant]
WO WO9819167 · 1998 [cited by applicant]
WO WO9819167A2 · 1998 [cited by applicant]
WO WO9824893 · 1998 [cited by applicant]
WO WO99051642 · 1999 [cited by applicant]
WO WO99051642A1 · 1999 [cited by applicant]
WO WO9954342 · 1999 [cited by applicant]
WO WO9954342A1 · 1999 [cited by applicant]
WO WO0042072 · 2000 [cited by applicant]
WO WO0042072A2 · 2000 [cited by applicant]
WO WO0158957 · 2001 [cited by applicant]
WO WO0158957A2 · 2001 [cited by applicant]
WO WO0206919 · 2002 [cited by applicant]
WO WO0206919A2 · 2002 [cited by applicant]
WO WO02068615 · 2002 [cited by applicant]
WO WO02068615A2 · 2002 [cited by applicant]
WO WO03035835 · 2003 [cited by applicant]
WO WO03041600 · 2003 [cited by applicant]
WO WO2003074679 · 2003 [cited by applicant]
WO WO03089616 · 2003 [cited by applicant]
WO WO04016750 · 2004 [cited by applicant]
WO WO04035752 · 2004 [cited by applicant]
WO WO2004029207 · 2004 [cited by applicant]
WO WO2004035752 · 2004 [cited by applicant]
WO WO2004035752A2 · 2004 [cited by applicant]
WO WO04063351 · 2004 [cited by applicant]
WO WO04074455 · 2004 [cited by applicant]
WO WO2004099249 · 2004 [cited by applicant]
WO WO05040217 · 2005 [cited by applicant]
WO WO05070963 · 2005 [cited by applicant]
WO WO05092925 · 2005 [cited by applicant]
WO WO06020114 · 2006 [cited by applicant]
WO WO2006068953 · 2006 [cited by applicant]
WO WO2006068953A2 · 2006 [cited by applicant]
WO WO2006133396 · 2006 [cited by applicant]
WO WO2006133396A2 · 2006 [cited by applicant]
WO WO2007055926 · 2007 [cited by applicant]
WO WO2008036981 · 2008 [cited by applicant]
WO WO2010069532 · 2010 [cited by applicant]
WO WO2010069532A1 · 2010 [cited by applicant]
WO WO2011014469 · 2011 [cited by applicant]
WO WO2011014469A1 · 2011 [cited by applicant]
WO WO2011063336 · 2011 [cited by applicant]
WO WO2013049517 · 2013 [cited by applicant]
WO WO2013117647 · 2013 [cited by applicant]
WO WO2014144791 · 2014 [cited by applicant]
WO WO2014144791A2 · 2014 [cited by applicant]
WO WO2014140904A2 · 2014 [cited by examiner]
Qi et al., Scandinavian J. of Immunol., 58:211-220, 2003. [cited by examiner]
Nassal et al. Int. J. of Med. Microbiol., 298:135-42, 2008. [cited by examiner]
Ali et al., Nature Materials 8:151-158, 2009. [cited by examiner]
Groh, V. et al., Efficient cross-priming of tumor anigen-specific T cells by dendritic cells sensistized with diverse anti-MICA opsonized tumor cells. Proc. Nat'l Acad. Sci., 102(18):6461-6466 (2005). [cited by applicant]
Jinushi, M. et al., “Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class lelated chain A in advanced human hepatocellular carcinomas”, J of Hepatology, 43:1013-1020 (2005). [cited by applicant]
Jinushi, M. et al., “Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity” Proc. Nat'l Acad. Sci., 103(24):9190-9195 (2006). [cited by applicant]
Balmana et al. “BRCA in breast cancer: ESMO Clinical Recommendations”, Annals of Oncology 20(supplement 4):v19-20 (2009). [cited by applicant]
Bednsten et al. “Improved Prediction of Signal Peptides: SignalP 3.0”, J Mol Biol 340(4) 783-95 (2004). [cited by applicant]
Dall'Acqua et et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)”, Journal of Biological Chemistry 281:23514-23524 (2006). [cited by applicant]
Wang, X. et al., “An six-amino acid motif in the .alpha.3 domain of MICA is the cancer therapeutic target to inhibit shedding,” Biochemical and Biophysical Research Communications, 387:476-481 (2009). [cited by applicant]
Pantazes, R.J. et al., “OptCDR: a general computational method for the design of antibody complementarity determining regions for targeting epitope binding,” Protein Engineering, Design & Selection, 23(11):849-353 (… [cited by applicant]
Sarmay et al. “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) through Different Types of Human Fc.gamma. Receptor”, Mol… [cited by applicant]
Shields, R.L. et al. “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fc.gamma. RIII and Antibody-dependent Cellular Toxicity”, J Biol. Chem. 277:26733-26740 (2002). [cited by applicant]
Tao et al., “Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation”, J. Exp. Med. 178:661 (1993). [cited by applicant]
Leblond et al.,“The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density ipoproteins to HepG2 cells,” J. Biol. Chem., 266 (10): 6058-6067 (1991). [cited by applicant]
Qi et al (Scandinavian Journal of Immunology, 2003, vol. 58, pp. 211-220) (Year: 2003). [cited by examiner]
Ali et al (Nature Materials, 2009, vol. 8, pp. 151-158) (Year: 2009). [cited by examiner]
Vetter et al (Journal of Investigative Dermatology, 2002, vol. 118, pp. 600-605) (Year: 2002). [cited by examiner]
Gonzalez et al (Annals of Oncology, 1998, vol. 9, pp. 431-435) (Year: 1998). [cited by examiner]
Nassal et al (International Journal of Medical Microbiology, 2008, vol. 298, pp. 135-142) (Year: 2008). [cited by examiner]
May et al., “Isolation of human anti-MICA antibody from cancer patients responding to immunotherapies,” Journal of Clinical Oncology, 30(15) Suppl., Abstract No. 2502 (2012). [cited by applicant]
Liu, G. et al., “Cutting Edge: The Membrane type Matrix Metal-loproteinase MMP14 Mediates Constitutive Shedding of MHC Class | Chain-Related Molecule A Independent of a Disintegrin and Metalloproteinases,” J. Immunol., … [cited by applicant]
U.S. Appl. No. 61/792,034, filed Mar. 15, 2013, Wucherpfennig et al. [cited by applicant]
U.S. Appl. No. 61/913,198, filed Dec. 6, 2013, Wucherpfennig et al. [cited by applicant]
Ali et al. “In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice”, Science Translation Medicine, 1, 8ra19, 12 pages (2009). [cited by applicant]
Altschul et al. “Basic Local Alignment Search Tool”, J. Mol. Biol., 215:403-10 (1990). [cited by applicant]
Almagro et al., “Humanization of antibodies”, Frontiers in Bioscience, 13:1619-33 (2008). [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25(17):3389-3402 (1997). [cited by applicant]
Amanna et al., “Duration of Humoral Immunity to Common Viral and Vaccine Antigens”, N. Engl. J. Med., 357:1903-1915, (2007). [cited by applicant]
Andrade et al., “Adsorption of complex proteins at interfaces”, Pure and Appl. Chem., 64(11):1777-1781 (1992). [cited by applicant]
Araya, C. L. et al., “Deep mutational scanning: assessing protein function on a massive scale,” Trends Biotechnol., 29(9), pp. 435-442 (2011). [cited by applicant]
Balazs et al., “Antibody-based protection against HIV infection by vectored immunoprophylaxis”, Nature, 481(7379):81-4 (2011). [cited by applicant]
Banchereau et al. “Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40”, Science 251 70 (1991). [cited by applicant]
Barbas, S. et al., “Recognition of DNA by Synthetic Antibodies,” J. Am. Chem. Soc., vol. 116(5), pp. 2161-2162 (1994). [cited by applicant]
Beiboer, S. et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent,” JMB, 296: 833-… [cited by applicant]
Benjamin et al. “The Antigenic Structure of Proteins: A Reappraisal”, Ann Rev Immunol 2 67-101, (1984). [cited by applicant]
Bergers et al., “Extrinsic regulators of epithelial tumor progression: metalloproteinases,” Curro Opinions in Genetics and Development, 10: 120-127 (2000). [cited by applicant]
Bird et al. “Single-Chain Antigen-Binding Proteins”, Science 242:423-426 (1988). [cited by applicant]
Bisman et al., “Long-term presence of memory B-cells specific for different vaccine components”, Vaccine, 28:179-186 (2009). [cited by applicant]
Bodey, B. et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,” Anticancer Research, 20: 2665-2676 (2000). [cited by applicant]
Boemer et al, “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes”, J Immunol, 147(1) 86 95 (1991). [cited by applicant]
Bordo et al. “Suggestions for “Safe” Residue Substitutions in Site-Directed Mutagenesis”, J. Mol. Biol. 217:721-729 (1991). [cited by applicant]
Brown, M. et al., “Tolerance to single, but not multiple, amino acid replacements in antibody VH CDR 2 a means of minimizing B cell wastage from somatic hypermutation?,” J Immunol., vol. 156(9), pp. 3285-3291 (1996). [cited by applicant]
Caine et al., “Recombinant Human Phenylethanolamine N-Methyltransferase: Overproduction in [cited by applicant]
Canfield “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region”, J. Exp. Med. 173:1483 (1991). [cited by applicant]
Cao et al., “An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body”, Journal of Immunological Methods, 358:56-65 (2010). [cited by applicant]
Casset, F. et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” BBRC, vol. 307, pp. 198-205(2003). [cited by applicant]
Champe et al. “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a”, The Journal of Biological Chemistry, 270:1388-1… [cited by applicant]
Chen, C. et al., “Generation and Analysis of Random Point Mutations in an Antibody CDR2 Sequence: Many Mutated Antibodies Lose Their Ability to Bind Antigen,” J Exp. Med., vol. 176, pp. 855-866 (1992). [cited by applicant]
Chen, Y. et al, “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fabin complex with antigen,” J Mol. Biol., vol. 293, pp. 865-881 (1999). [cited by applicant]
Cheung et al., “Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks”, Virology 176:546 (1990). [cited by applicant]
Chin et al., “Immune intervention with monoclonal antibodies targeting CD152 {CTLA-4) for autoimmune and malignant diseases,” Chang Gung Med J., 31 (1): 1-15 (2008). [cited by applicant]
Choi et al., “Evolutionary conservation in multiple faces of protein interaction”, Proteins: Structure, Function, and Bioinformatics, 77(1):14-25 (2009). [cited by applicant]
Chothia et al., “Conformations of immunoglobin hypervariable regions”, Nature, 342:877-883 (1989). [cited by applicant]
Chothia, C. et al., “Structural Repertoire of the Human VH Segments,” J Mol. Biol., vol. 227, pp. 799-817 (1992). [cited by applicant]
Chothia et al. “Canonical Structures for the Hypervariable Regions”, J Mol Biol 196 901-917 (1987). [cited by applicant]
Clackson et al, “Making antibody fragments using phage display libraries”, Nature, 352 624-628 (1991). [cited by applicant]
Cole et al, “The EBV-Hybridoma Technique and its Application to Human Lung Cancer”, Monoclonal Antibodies and Cancer Therapy, p. 77-96 (1985). [cited by applicant]
Corada et al., “Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability”, Blood; 97:1… [cited by applicant]
Corti et al., “Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals”, PLoS One, 5:e8805 (2010). [cited by applicant]
Cox et al., “Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor”, Nat. Biotechnol 24(12): 1591-7 (2006). [cited by applicant]
Cox, J. P. L. et al. “A Directory of Human Germ-line VH Segments Reveals a Strong Bias in their Usage” Eur. J Immunol. 24:827-836 (1994). [cited by applicant]
Crotty et al., “Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination” J. Immunol., 171:4969-4973 (2003). [cited by applicant]
Cunningham et al. “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”, Science 244: 1081-1085 (1989). [cited by applicant]
Dall'Acqua et al. “Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences”, Journal of Immunology, 169:5171-5180 (2002). [cited by applicant]
De Genst et al., “Antibody repertoire development in camelids”, Dev Comp Immunol; 30:187-98 (2006). [cited by applicant]
De Pascalis, R. et al, “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody… [cited by applicant]
De Ridder G. et al. “Cell-Surface GRP78 and its Antibodies: Pathologic and Therapeutic Roles in Cancer”, 2010. Retrieved from the Internet: URL:http://dukespace.lib.duke.edu/dspace/bitstream/handle/10161 /3805/deRidder_… [cited by applicant]
Dennis, C. “Off by a whisker”, Nature, vol. 442, pp. 739-741 (2006). [cited by applicant]
Ditzel, H. et al., “Determinants of Polyreactivity in a Large Panel of Recombinant Human Antibodies from HIV-Infection,” The Journal of Immunology, vol. 157, pp. 739-749, (1996). [cited by applicant]
Doubrovina et al., “Evasion from NK Cell Immunity by MHC Class I Chainrelated Molecules Expressing Colon Adenocarcinoma,” J Immunol, 171:6891-9 (2003). [cited by applicant]
Duncan et al., “Localization of the binding site for the human high-affinity Fe receptor on IgG”, Nature 332:563 (1988). [cited by applicant]
Duquesnoy, R. et al., “Structurally based epitope analysis of major histocompatibility complex class I-related chain A (MICA) antibody specificity patterns,” Human Immunology, vol. 69:826-832 (2008). [cited by applicant]
Emim et al. “Antigenic Conservation and Divergence between the Viral-Specific Proteins of Poliovirus Type 1 and Various Picornaviruses”, Virology 140 13-20 (1985). [cited by applicant]
Fang et al. “Stable antibody expression at therapeutic levels using the 2A peptide”, Nature Biotechnology 23, 584-590 ((2005). [cited by applicant]
Fecteau et al., “Peripheral blood CD27+ IgG+ B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction”, Immunology, 128:e353-e365 30 (2009). [cited by applicant]
Fields et al., Chapter 3 “Synthetic Peptides: A User's Guide”, p. 77 (1992). [cited by applicant]
Fishwild et al, “High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice”, Nature Biotechnology 14, 845-51 (1996). [cited by applicant]
Fonseca, C. et al., “Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction”, Blood, vol. 113, pp. 1681-1688 (2009). [cited by applicant]
Franz et al. “Ex vivo characterization and isolation of rare memory B cells with antigen tetramers”, Blood, 118(2):348-357 (2011). [cited by applicant]
Germain, C. et al., “MHC Class I-Related Chain a Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells,” Clinical Cancer Research, The American Association for Cancer Res… [cited by applicant]
Getzoff et al. “The Chemistry and Mechanism of Antibody Binding to Protein Antigens”, Advances in Immunology 43:1-98, (1988). [cited by applicant]
Gillies S.D. et al., “Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors”, Cancer Res. 59:2159-66 (1999). [cited by applicant]
Girlanda, S. et al., “MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-activated Gammadelta Lymphocytes,” Cancer Research, vol. 65 (16), pp.… [cited by applicant]
Gong et al., “A protein domain interaction interface database: InterPare”, BMC: Bioinformatics, 6:1471-2105 (2007). [cited by applicant]
Groh et al., “Tumour-derived Soluble MIC Ligands Impair Expression of NKG2D and T-cell Activation,” Nature 419: 734-8 (2002). [cited by applicant]
Groh, V. et al., “Broad tumor-associated expression and recognition by tumor-derived gammadelta T cells of MICA and MICB,” Proc. Natl. Acad. Sci. USA, vol. 96:6879-6884 (1999). [cited by applicant]
Groh, V. et al., “Cell stress-regulated human major histocompatibility complex class I gene expressed in Jastrointestinal epithelium,” Proc. Natl. Acad. Sci. USA, 93:12445-12450 (1996). [cited by applicant]
Groh, V. et al., “Recognition of Stress-Induced MHC Molecules by Intestinal Epithelial gammadelta T Cells,” Science, 279:1737-1740 (1998). [cited by applicant]
Guo et al., “Protein tolerance to random amino acid change”, Proc. Natl. Acad. Sci., USA, 101(25):9205-9210 (2004). [cited by applicant]
Gura, T. “Systems for Identifying New Drugs are Often Faulty”, Science, 278: 1041-1042 (1997). [cited by applicant]
Hara et al., “Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity,” Cancer Sci., 99 (… [cited by applicant]
Henn et al., “Modulation of Single-Cell IgG Secretion Frequency and Rates in Human Memory B Cells by CpG DNA, CD40L, IL-21, and Cell Division”, J. Immunol., 183:31777-3187 (2009). [cited by applicant]
Hinton et al. “An Engineered Human IgG1 Antibody with Longer Serum Half-Life”, Journal of Immunology 176:346-356 (2006). [cited by applicant]
Hinton et al., “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates”, J. Biol. Chem. 279(8): 6213-6216 (2004). [cited by applicant]
Hofer et al., Adaptation of humoral memory, Immunological Reviews, 211:295-302 (2006). [cited by applicant]
Hofmann et al. “A database of membrane spanning proteins segments”, Biol Chem Hoppe-Seyler 374,166 (1993). [cited by applicant]
Holm, P. et al. “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1” Mol. Immunol., 44:1075-1084 (2007). [cited by applicant]
Hoogenboom et al. “Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro”, J Mol Biol, 227 381 (1991). [cited by applicant]
Hopp et al. “A computer program for predicting protein antigenic determinants”, Molecular Immunology 20 483-489 (1983). [cited by applicant]
Hopp et al. “Prediction of protein antigenic determinants from amino acid sequences”, Proc Natl Acad Sci USA 78 3824-3828 (1981). [cited by applicant]
Hopp, Methods for identifying antigenic determinants and other interaction sites, Immunol Methods 88 1-18 (1986). [cited by applicant]
Hue, S. et al., “Potential Role of NKG2D/MHC Class I-Related Chain A Interaction in Intrathymic Maturation of Single-Positive COB T Cells,” The Journal of Immunology, 171:1909-1917 (2003). [cited by applicant]
Huergo-Zapico L. et al. “Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding”, Cancer Immunology, Immunotherapy, 61(8):1201-1210 (2012). [cited by applicant]
Huggins et al., “CpG DNAactivation and plasma-cell differentiation of CD27_naïve human B cells”, Blood, 109:1611-1619 (2007). [cited by applicant]
Huston et al. “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Jaeger et al., “Improved predictions of secondary structures for RNA”, Proc. Natl. Acad. Sci. USA 86:7706-10 (1989). [cited by applicant]
Jaeger et al., “Predicting Optimal and Suboptimal Secondary Structure for RNA”, Methods Enzymol. 183:281-306 (1989). [cited by applicant]
Jameson, et al. The antigenic index: a novel algorithm for predicting antigenic determinants, Comput Appl Biosci 4(1) 181-186 (1988). [cited by applicant]
Jespers et al., “Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen”, Biotechnology 12:899, (1994). [cited by applicant]
Jiang, B. et al., “A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2”, J. Biol. Chem., 280(6):4656-4662 (2005). [cited by applicant]
Jiang, et al., “TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function”, Eur. J. Immunol., 37:2205-2213 (2007). [cited by applicant]
Jinushi, M. et al. “MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma”, PNAS, 105:1285-1290 (2008). [cited by applicant]
Jinushi, M. et al., “Enhancing the clinical activity of granulocyte-macrophage colony stimulating factor-secreting tumor cell vaccines”, Immunological Reviews, 222:287-298 (2008). [cited by applicant]
Johnson et al. A Structural Basis for Sequence Comparisons: An Evaluation of Scoring Methodologies, J. Mol. Biol. 233:716-738 (1993). [cited by applicant]
Jones, P. et al. “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Nature 321:522-525 (1986). [cited by applicant]
Jordan, Peter A. et al., “A role for the thiol isomerase protein ERP5 in platelet function,” Blood, 105(4):1500-1507 (2005). [cited by applicant]
Jourdan et al., “An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization”, Blood, 114:5173-5181 (2009). [cited by applicant]
Kaiser et al., “Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands”, Nature, 447 (7143):182-486 (2007). [cited by applicant]
Kalos M, et al., “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”, Sci Transl Med. Aug. 10;3 (95), (2011). [cited by applicant]
Kaneko et al., “Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation”, Science 313:670-673 (2006). [cited by applicant]
Kelland, L.R. “Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development”, Eur. J Cancer, vol. 40 (6), pp. 827-836 (2004). [cited by applicant]
Kettleborough et al, “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation”, Protein Eng 4(7) 773 83 (1991). [cited by applicant]
Kirkland et al., “Analysis of the Fine Specificity and Cross-Reactivity of Monoclonal Anti-Lipid A Antibodies”, J Immunol. 137:3614 (1986). [cited by applicant]
Klimka, A., et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer, vol. 83(2), pp. 252-260 (2000). [cited by applicant]
Klinman “CpG DNA as a vaccine adjuvant”, Expert Review Vaccines 2(2):305-15 (2003). [cited by applicant]
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”, Journal of Immunol. 148, 1547-1553 (1992). [cited by applicant]
Kratz et al. “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids”, Proc Natl Acad Sci USA. 96(5):1915-1920 (1999). [cited by applicant]
Krogh et al. “Predicting transmembrane protein topology with a hidden Markov model Application to complete genomes”, Journal of Molecular Biology, 305(3) 567-580, (2001). [cited by applicant]
Kunkel et al., “Plasma-Cell Homing”, Nat. Rev. Immunol., 3:822-829 (2003). [cited by applicant]
Kuo et al.,“Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics,” Hybridoma, 31 (2): 77-86 (2012). [cited by applicant]
Kyte et al. “A Simple Method for Displaying the Hydropathic Character of a Protein”, J Mol Biol 157 105-132 (1982). [cited by applicant]
Lanzavecchia et al., “Human B cell memory”, Curr. Opin. Immunol. 21:298-304 (2009). [cited by applicant]
Leblond et al.,“The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells,” J. Biol. Chem., 266 (10): 6058-6067 (1991). [cited by applicant]
Li et al., “Human B cell memory”, Nature Biotechnology 24(2):210-215 (2006). [cited by applicant]
Liu et al. “Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis”, The Journal of Clinical Investigation 123(10):4410-4422 (2013). [cited by applicant]
Liu et al.,“The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain related molecule A independent of A disintegrin and metalloproteinases,” J. Immunol. 184 (7): 3346-3350 (2… [cited by applicant]
Liu R. et al. “Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing P13K/AKT Signaling, Tumor Growth, and Metastasis”, Clinical Cancer Research, 19(24):6802-6811 (2013). [cited by applicant]
Lonberg “Human antibodies from transgenic animals”, Nature Biotechnology 23(9): 1117-1125, (2005). [cited by applicant]
Lonberg et al, “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature 368 856-859 (1994). [cited by applicant]
Lonberg et al, “Human Antibodies from Transgenic Mice”, International Reviews of Immunology, 13 65-93 (1995). [cited by applicant]
MacCallum “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, J. Mol. Biol, 262, 732-745 (1996). [cited by applicant]
Makabe et al., “Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528”, Journal of Biological Chemistry, 283:1156-1166 (2008). [cited by applicant]
Marks et al, “By-Passing Immunication: Building High Affinity Human Antibodies by Chain Shuffling”, Bio/Technology 10, 779-783 (1992). [cited by applicant]
Marks et al, “Human Antibodies from V-gene Libraries Displayed on Phage”, J Mol Biol, 222 581-597 (1991). [cited by applicant]
Marten et al., “Soluble MIC is Elevated in the Serum of Patients with Pancreatic Carcinoma Diminishing Gamma Delta T Cell Cytotoxicity,” Int J Cancer 119:2359-65 (2006). [cited by applicant]
Martin, D., et al., “Symposium on Cancer Immunology and Immunotherapy,” Roche/Nature Medicine, 91 pages (2011). [cited by applicant]
McCafferty et al, “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature, 348 552-554 (1990). [cited by applicant]
Mei et al., “Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and heir effects on cytotoxicity of natural killer cells,” Nan Fang Yi Ke Da Xue Xue Bao., 27 (6):887-889 (2007… [cited by applicant]
Meyers E. et al. “Optimal alignments in linear space”, CABIOS, 4:11-17 (1989). [cited by applicant]
Milone et al. “Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo”, Mol. Ther. 17:1453 (2009). [cited by applicant]
Moldenhauer et al., “Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia”, Scand. J Immunol. 32:77 (1990). [cited by applicant]
Moms et al. “Genetically Engineered Antibody Molecules”, Advances in Immunology 44 65-92 (1988). [cited by applicant]
Momson et al. “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc Natl Acad Sci. USA. 81 6851-685 5 (1984). [cited by applicant]
Morel et al., “Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations”, Mol. Immunol. 25(1):7 (1988). [cited by applicant]
Morrison et al, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc Natl Acad Sci USA, 81 6851-6855 (1984). [cited by applicant]
Morrison, “Success in Specification”, Nature 368, 812-13 (1994). [cited by applicant]
Nausch et al., “NKG2D ligands in tumor immunity,” Oncogene, 27:5944-5958 (2008). [cited by applicant]
Nechansky et al., “Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies”, Molecular Immunology 44(7): 1815-1817 (2007). [cited by applicant]
Needleman et al. “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
Nelson et al., “Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies,” Cancer Chemother. Pharmacol.,… [cited by applicant]
Neuberger, “Generating high-avidity human Mabs in mice”, Nature Biotechnology 14,826 (1996). [cited by applicant]
Odendahl et al., “Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response”, Blood, 105:1614-1621 (2005). [cited by applicant]
Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties”, Molecular Immunology, 28 489-498 (1991). [cited by applicant]
Padlan, “Anatomy of the Antibody Molecule”, Molecular Immunology 31(3) 169-217 (1994). [cited by applicant]
Padlan, “X-Ray Crystallography of Antibodies”, Advances in Protein Chemistry 49:57-133 (1996). [cited by applicant]
Pantazes, R.J. et al., “OptCDR: a general computational method for the design of antibody complementarity determining regions for targeting epitope binding,” Protein Engineering, Design & Selection, 23(11):849-353 (2010… [cited by applicant]
Park et al., “Prediction of protein-protein interaction types using association rule based classification”, BMC: Bioinformatics, 10:1471-2105 (2009). [cited by applicant]
Pashine et al. “Targeting the innate immune response with improved vaccine adjuvants”, Nature Med. 11(4):S63-S68 (2005). [cited by applicant]
Pearson et al. “Improved tools for biological sequence comparison”, Proc. Natl. Acad. Sci. USA 85:2444 (1988). [cited by applicant]
Pearson, “Rapid and Sensitive Sequence Comparison with FASTP and FASTA”, Meth. Enzymology, 183:63-98 (1990). [cited by applicant]
Pende et al.,“Major histocompatibility complex class I-related chain A and UL 16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer… [cited by applicant]
Pettersen et al., “CD47 signals T cell death,” J. Immunol., 162 (12):7031-7040 (1999). [cited by applicant]
Phumyen, A. et al., “Improved Binding Activity of Antibodies Against Major Histocompatibility Complex Class I Chain Related Gene A by Phage Display Technology for Cancer-Targeted Therapy,” Journal of Biomedicine and Bio… [cited by applicant]
Pluckthun, “Mono- and Bivalent Antibody Fragments Produced in [cited by applicant]
Ponsel, Dirk et al., “High Affinity, Developability and Functional Size: The Holy Grail of Combinatorial Antibody Library Generation,” Molecules, 16: 3675-3700 (2011). [cited by applicant]
Queen, C. et al. “A humanized antibody that binds to the interleukin 2 receptor”, Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989). [cited by applicant]
Rader, C. et al., “A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,” PNAS, USA, vol. 95, pp. 8910-8915 (1998). [cited by applicant]
Riechmann, L. et al. “Reshaping human antibodies for therapy”, Nature 332:323-327 (1998). [cited by applicant]
Riemer, A. et al. “Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition”, Mol. Immunol, 42:1121-1124 (2005). [cited by applicant]
Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA, 79:1979-1983 (1982). [cited by applicant]
Saijo, N., “What are the reasons for negative phase III trials of molecular-target-based drugs?”, Cancer Sci., 95 (10):772-776 (2004). [cited by applicant]
Salih, Helmut R. et al., “Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding,” The Journal of Immunology, 169:4098-4102 (2002). [cited by applicant]
Salih, Helmut R. et al., “Functional expression and release of ligands for the activating immunoreceptor NKG2D in Leukemia,” Blood, 102(4):1389-1396 (2003). [cited by applicant]
Sarmay et al. “Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) through Different Types of Human Fcy Receptor”, Molec. Im… [cited by applicant]
Scallon et al., “Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality”, Mol Immunol. 44(7): 1524-34 (2007). [cited by applicant]
Scatchard, “The attractions of proteins for small molecules and ions”, Ann NY Acad Sci 51 660-672, (1949). [cited by applicant]
Scheid et al., “Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals”, Nature, 458:636-640 (2009). [cited by applicant]
Schoenfeld J. et al., “Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis,” Microenvironment and Immunology, Cancer Research, 70(24):10150-10160 (2010). [cited by applicant]
Shields, R.L. et al. “High Resolution Mapping of the Binding Site on Human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR”, J Biol. Chem. 276:6591-6604 (2001). [cited by applicant]
Shields, R.L. et al. “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity”, J Biol. Chem. 277:26733-26740 (2002). [cited by applicant]
Sircar, A. et al., “Rosetta Antibody: antibody variable region homology modeling server,” Nucleic Acids Research, vol. 37, pp. W474-W479 (2009). [cited by applicant]
Skerra et al., “Bacterial expression of immunoglobulin fragments”, Curr. Opinion in Immunol., 5:256-262 (1993). [cited by applicant]
Smith et al. “Comparison of Biosequences”, Advances in Applied Mathematics, 2:482 (1981). [cited by applicant]
Songsivilai et al. “Bispecific antibody: a tool for diagnosis and treatment of disease”, Clin. Exp. Immunol. 79:315-321 (1990). [cited by applicant]
Stahli et al.,“Distinction of Epitopes by Monoclonal Antibodies”, Methods in Enzymology 92:242-253 (1983). [cited by applicant]
Steinle, A. et al., “Diversification, expression, and gammadelta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules,” Proc. Natl. Acad. S… [cited by applicant]
Strohl, “Optimization of Fc-mediated effector functions of monoclonal Antibodies”, Current Opinion in Biotechnology 20:685-691 (2009). [cited by applicant]
Suarez-Alvarez, B. et al., “Identification of epitopes and immunodominant regions on the MICA protein defined by alloantibodies from kidney transplant patients,” Transplantation, Williams and Wilkins, GB, 88 (3) Suppl, … [cited by applicant]
Tang, B. et al., “Evaluation of human major histocompatibility complex class I chain-related A as a potential target for tumor imaging,” Cancer Letters, New York, NY, US, vol. 263 (1), pp. 99-106 (Jan. 30, 2008). [cited by applicant]
Tao et al. “Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region”, J. Immunol. 143:2595-2601 (1989). [cited by applicant]
Tao et al., “Structural Features of Human Immunoglobulin G that Determine Isotype-specitic Differences in Complement Activation”, J. Exp. Med. 178:661 (1993). [cited by applicant]
Taylor, The Classification of Amino Acid Conservation, J. Theor. Biol. 119:205-218 (1986). [cited by applicant]
Thom, George et al., “Probing a protein-protein interaction by in vitro evolution,” PNAS, vol. 103(20):7619-7624 (2006). [cited by applicant]
Tomlinson, I. M., et al. “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops” J. Mol. Biol. 227:776-798 (1992). [cited by applicant]
Umana et al. “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity”, Nat. Biotech. 17:176-180 (1999). [cited by applicant]
Vajdos, FF et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J Mol Biol. 320(2):415-428 (2002). [cited by applicant]
Verhoeyen et al, “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science 239 1534 1536 (1988). [cited by applicant]
Vitetta, Ellen S. et al., “Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy,” Cancer Research, 54:5301-5309 (1994). [cited by applicant]
Wang et al. “Role of the Unfolded Protein Response Regulator GRP78/BiP in Development, Cancer, and Neurological Disorders”, Antioxidants and Redox Signaling 11(9): 2307-2316 (2009). [cited by applicant]
Wang et al., “Human immunoglobulin variable region gene analysis by single cell RT-PCR”, J. Immunol. Methods, 244:217-225 (2000). [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Weber, “Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related advers events,” Oncologist, 12(7): 864-872 (2007). [cited by applicant]
Whiteside, T. et al., “Antigen-Processing Machinery in Human Dendritic Cells; Up-regulation by Maturation and Down-Regulation by Tumor Cells,” J Immunol., vol. 173, pp. 1526-1534 (2004). [cited by applicant]
Wongsena et al “Production and characterization of monoclonal antibodies against major histocompatibility complex class 1 chain-related gene A,” Tissue Antigens, 72(5):431-440 (2008). [cited by applicant]
Wu et al., “Prevalent Expression of the Immunostimulatory MHC Class I Chain-related Molecule is Counteracted by Shedding in Prostate Cancer,” J Clin Invest 114: 560-8 (2004). [cited by applicant]
Wu et al., “Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1”, Science, 329:856-861 (2010). [cited by applicant]
Yeung et al., “Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates”, J Immunol, 182:7663-7671 (2010). [cited by applicant]
Yoshida et al., “Memory B and memory plasma Cells”, Immunol. Rev., 237:117-139 (2010). [cited by applicant]
Yu et al. “Minimal Lipidation Stabilizes Protein-Like Molecular Architecture”, J Am. Chem. Soc., 120(39):9979-9987 (1998). [cited by applicant]
Zapata et al, “Engineering linear F(ab′)2 fragments for efficient production in [cited by applicant]
Zou, Yizhou et al., “MICA is a Target for Complement-Dependent Cytotoxicity With Mouse Monoclonal Antibodies and Human Alloantibodies,” Human Immunology, 63:30-39 (2002). [cited by applicant]
Zuker, “On Finding All Suboptimal Foldings of an RNA Molecule”, Science 244:48-52 (1989). [cited by applicant]
Zwirner, N. et al., “Immunobiology of the human AMC class I chain-related gene A (MICA): from transplantation immunology to tumor immune escape,” Immunologia, 25(1):25-38 (2006). [cited by applicant]
Morrison et al., “Genetically Engineered Antibody Molecules”, Advances in Immunology, vol. 44, p. 65-92 (1988). [cited by applicant]
Spear et al., “NKG2D ligands as therapeutic targets”, Cancer Immunity, vol. 13, p. 1-14 (May 1, 2013). [cited by applicant]
Wang, X. et al., “An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit shedding,” Biochemical and Biophysical Research Communications, 387:476-481 (2009). [cited by applicant]